Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.
Wang, L., Pratt, J.K., Soltwedel, T., Sheppard, G.S., Fidanze, S.D., Liu, D., Hasvold, L.A., Mantei, R.A., Holms, J.H., McClellan, W.J., Wendt, M.D., Wada, C., Frey, R., Hansen, T.M., Hubbard, R., Park, C.H., Li, L., Magoc, T.J., Albert, D.H., Lin, X., Warder, S.E., Kovar, P., Huang, X., Wilcox, D., Wang, R., Rajaraman, G., Petros, A.M., Hutchins, C.W., Panchal, S.C., Sun, C., Elmore, S.W., Shen, Y., Kati, W.M., McDaniel, K.F.(2017) J Med Chem 60: 3828-3850
- PubMed: 28368119 
- DOI: https://doi.org/10.1021/acs.jmedchem.7b00017
- Primary Citation of Related Structures:  
5UEU, 5UEW, 5UEX, 5UEY, 5UEZ, 5UF0 - PubMed Abstract: 
Members of the BET family of bromodomain containing proteins have been identified as potential targets for blocking proliferation in a variety of cancer cell lines. A two-dimensional NMR fragment screen for binders to the bromodomains of BRD4 identified a phenylpyridazinone fragment with a weak binding affinity (1, K i = 160 μM) ...